Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
To determine if treatment with BG00012 can decrease the number of MS relapses during a
certain time period. Other goals of the study are to determine if, over time, BG00012
treatment can decrease the number of certain types of brain lesions commonly seen in MS
patients and slow down the time it takes for MS to get worse.
Other objectives of the study are to determine the safety and tolerability of BG00012, as
well as the effect it may have on tests and evaluations used to assess MS. Additionally,
glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.